Published in Cancer Weekly, May 12th, 2009
“The preclinical data for CUDC-305 continue to support seeking to advance the drug toward clinical testing. It has unique pharmacological properties and demonstrated efficacy in preclinical models across a diverse number of solid and hematological tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.